Group Oncostat – UMR1018 - Villejuif

Who are we?

The group ONCOSTAT is a part of the UMR 1018/CESP (http://cesp.inserm.fr/).
The recent revolution in –omics technology and the advent of targeted therapies have increased the interest in molecular biomarkers capable of predicting the diagnostic, the clinical outcome of cancer patients or the response to specific therapies (diagnostic, prognostic and predictive). There are many challenges in the appropriate processing of modern sequencing data and the integration of molecular data in clinical epidemiology. The development of personalised medicine implies the segmentation of common cancers in small groups of tumours with specific abnormalities.

Research theme 1 « Clinical Trial Methodology »
A new generation of clinical trial designs requiring repeated biomarker measurements and surrogate clinical endpoints is needed to evaluate treatment effects in trials with limited sample sizes

Research theme 2 « Meta-analysis of treatments and biomarkers »
Large-scale collaborative individual patient data meta-analyses are useful tools to provide high level of evidence on the efficacy and toxicity of anti-cancer therapies in molecularly defined strata.

Research theme 3 « Economic evaluation of treatments and biomarkers »
With the increasing number of therapies available for a specific indication in oncology, methods for network meta-will be developed to compare their effectiveness. Because of the high costs associated with the new tandem diagnostic and therapeutic medicine, economic analyses will be needed to evaluate the strategy associating the biomarkers with the molecularly targeted treatments, which represents a new field of research

Research theme 4 « Molecular cancer epidemiology »
Once a potential biomarker has been identified for the prediction of diagnosis or clinical outcome of patients, evidence-based evaluation implies careful replication in other cohorts. Advances in molecular genetics and in the knowledge of pathology of cancer are re-shaping the traditional methods in clinical and molecular epidemiology research.
https://www.gustaveroussy.fr/fr/content/méthodologie-et-epidémiologie-clinique-en-oncologie-moléculaire-thématique

Main publications

• Bayar MA, Le Teuff G, Michiels S, Sargent DJ, Le Deley MC. New insights into the evaluation of randomized controlled trials for rare diseases over a long-term research horizon: a simulation study. Stat Med. 2016 Aug 30;35(19):3245-58.
• Ternès N, Rotolo F, Michiels S. Empirical extensions of the lasso penalty to reduce the false discovery rate in high-dimensional Cox regression models. Stat Med. 2016 Jul 10;35(15):2561-73.
• Paoletti X, Doussau A, Ezzalfani M, Rizzo E, Thiébaut R. Dose finding with longitudinal data: simpler models, richer outcomes. Stat Med. 2015 Sep 30;34(22):2983-98.
• Doussau A, Geoerger B, Jiménez I, Paoletti X. Innovations for phase I dose-finding designs in pediatric oncology clinical trials. Contemp Clin Trials. 2016 Mar;47:217-27
• Marguet S, Mazouni C, Ramaekers BL, Dunant A, Kates R, Jacobs VR, Joore MA, Harbeck N, Bonastre J. European cost-effectiveness study of uPA/PAI-1 biomarkers to guide adjuvant chemotherapy decisions in breast cancer. Eur J Cancer. 2016 Jun 17;63:168-179.
• Borget I, Bonastre J, Catargi B, Déandréis D, Zerdoud S, Rusu D, Bardet S, Leenhardt L, Bastie D, Schvartz C, Vera P, Morel O, Benisvy D, Bournaud C, Bonichon F, Kelly A, Toubert ME, Leboulleux S, Journeau F, Benhamou E, Schlumberger M. Quality of Life and Cost-Effectiveness Assessment of Radioiodine Ablation Strategies in Patients With Thyroid Cancer: Results From the Randomized Phase III ESTIMABL Trial. J Clin Oncol. 2015 Sep 10;33(26):2885-92.
• Blanchard P, Lee A, Marguet S, Leclercq J, Ng WT, Ma J, Chan AT, Huang PY, Benhamou E, Zhu G, Chua DT, Chen Y, Mai HQ, Kwong DL, Cheah SL, Moon J, Tung Y, Chi KH, Fountzilas G, Zhang L, Hui EP, Lu TX, Bourhis J, Pignon JP; MAC-NPC Collaborative Group. Chemotherapy and radiotherapy in nasopharyngeal carcinoma: an update of the MAC-NPC meta-analysis. Lancet Oncol. 2015 Jun;16(6):645-55

Contact us

Equipe Oncostat CESP, INSERM, Univ. Paris-Sud
Service de Biostatistique et d’Epidémiologie
Gustave Roussy, B2M RDC
114 rue Edouard Vaillant
94805 Villejuif cedex
France
stefan.michiels@gustaveroussy.fr
xavier.paoletti@gustaveroussy.fr